Targeting Stat3 With G-Quartet Oligonucleotides in Metastic Prostate Cancer
Final rept. 1 Apr 2003-31 Mar 2006
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
During the three year funding period, we have well developed a novel and potent Stat3 inhibitor, which represents a promising class of anti-cancer drug in treatment of human cancers, including prostate, breast, head and neck, and long cancers. We appreciate to get a DOD funding for supporting this project. However, the funding period is too short to fulfill the preclinical drug development.
- Anatomy and Physiology
- Medicine and Medical Research